drugset / Trial / NCT00131651
ATN-161 in Advanced Renal Cell Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine an active dose of ATN-161 for future studies while establishing preliminary evidence of effectiveness in patients with renal cell cancer.
Timeline
- Start
- 2005-08
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATN-161 | Protein / enzyme biologic | 20 mg | Intravenous |
| Subject | ATN-161 | Protein / enzyme biologic | 100 mg | Intravenous |
| Subject | ATN-161 | Protein / enzyme biologic | 600 mg | Intravenous |